Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
EV/Core EBITDA

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Top Undervalued Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   EV/Core EBITDA(x) 19.1713.5429.1926.12-1.19

What is the latest EV/Core EBITDA ratio of GLAND PHARMA ?

The latest EV/Core EBITDA ratio of GLAND PHARMA is 19.17 based on Mar2024 Consolidated results.
Year EV/Core EBITDA
Mar202419.17
Mar202313.54
Mar202229.19
Mar202126.12
Mar2020-1.19

How is EV/Core EBITDA of GLAND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2024 19.17
41.58
Mar2023 13.54
-53.61
Mar2022 29.19
11.75
Mar2021 26.12
Positive
Mar2020 -1.19 -

Other Financial Ratios of GLAND PHARMA


Compare EV/Core EBITDA ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹23,741.1 Cr -13.2% -20.4% -17.4% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹428,461.0 Cr 1.4% -4.1% 32.1% Stock Analytics
DIVIS LABORATORIES ₹147,983.0 Cr -4.2% -5.1% 59.6% Stock Analytics
CIPLA ₹112,735.0 Cr -2.2% -7.3% 0.2% Stock Analytics
DR REDDYS LABORATORIES ₹99,913.9 Cr -7.1% -13.8% 8% Stock Analytics
ZYDUS LIFESCIENCES ₹92,815.0 Cr -6.4% -5.2% 31.2% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-13.2%

-20.4%

-17.4%

SENSEX

-2.2%

-4%

5.5%


You may also like the below Video Courses